AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.
Biopharmaceuticals giant Bristol Myers Squibb has announced it is spending $14bn to purchase Karuna Therapeutics, which develops treatments for people living with psychiatric and neurological conditions.
Swiss telecommunications firm Swisscom has been mulling over an offer for Vodafone's Italian operations early next year, according to Bloomberg, potentially countering a rival bid from Iliad SA.
Harbour Energy surged on Thursday after saying it has agreed to buy the upstream assets of German oil and gas producer Wintershall Dea from shareholders BASF and LetterOne for $11.2bn.